- Shehnaz Ahmed, PhD, Advanced Instruments, UK
With the ever-increasing demand to develop and deliver new cell and gene therapies to market, pharmaceutical companies are under growing pressure to improve the efficiency of their cell line development campaigns. Engineering increasingly complex stable cell lines whilst maintaining high cell viability, and product quality is a challenge that persists within the bioprocessing industry. Learn how the Solentim portfolio, presented by Advanced Instruments, can optimize cloning efficiencies, support INDs with high-resolution image-based clonality assurance, apply AI-based algorithms for data analysis and support clonal expansion for scalable manufacture. Join as we streamline the development of stable cell lines and ensure unparalleled growth and performance.
Session Objectives:
- Understanding the best practices for developing stable cell and gene therapies
- Maximize cloning efficiencies
- Fast-track IND submissions with image-based assurance of clonality
- Leveraging artificial Intelligence for data analysis
- Future-proof workflows for GMP compatibility
SPONSORED BY:
